---
document_datetime: 2023-09-21 18:44:02
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/olysio-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: olysio-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.4148728
conversion_datetime: 2025-12-28 00:37:19.983776
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## OLYSIO

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                               | Opinion/ Notification 1 issued on Decision Issued amended on no   | Commission 2 / Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10255 /201705  | Periodic Safety Update EU Single assessment - simeprevir                                                                                                                                                            | 14/12/2017 08/02/2018                                             | SmPC                                            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10255/201705. |
| IA/0033              | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) 28/07/2017 product | n/a                                                               |                                                 |                                                                                                                                            |

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

| II/0031             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 20/07/2017   | 11/01/2018    | SmPC                  |                                                                                                                                             |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10255 /201611 | Periodic Safety Update EU Single assessment - simeprevir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 09/06/2017   | n/a           |                       | PRAC Recommendation - maintenance                                                                                                           |
| N/0032              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 24/03/2017   | 11/01/2018    | PL                    |                                                                                                                                             |
| IA/0030             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/03/2017   | n/a           | longer                |                                                                                                                                             |
| A20/0019            | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested the opinion of the European Medicines Agency further to a signal of hepatitis B reactivation in patients co- infected with HBV/HCV and concerns over the recurrence of hepatocellular carcinoma in patients using direct-acting antivirals in the context of interferon-free treatment of chronic hepatitis C. The PRAC was requested to assess the impact thereof on the benefit-risk balance of authorised direct-acting antivirals, namely Daklinza, Exviera, Harvoni, Olysio, Sovaldi and Viekirax and to give its opinion on whether the marketing authorisation of these products should be maintained, varied, suspended or revoked. product | 15/12/2016   | 23/02/2017 no | SmPC, Annex II and PL | Please refer to the assessment report: Direct-acting antivirals indicated for treatment of hepatitis C (interferon-free) - EMEA/H/A-20/1438 |

<div style=\"page-break-after: always\"></div>

| II/0027/G           | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                              | 19/01/2017   | 11/01/2018    | SmPC               |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|--------------------|-----------------------------------|
| IB/0028             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/12/2016   | 23/02/2017    | SmPC and PL longer |                                   |
| N/0026              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                    | 09/12/2016   | 23/02/2017 no | Labelling and PL   |                                   |
| PSUSA/10255 /201605 | Periodic Safety Update EU Single assessment - simeprevir                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 01/12/2016   | n/a           |                    | PRAC Recommendation - maintenance |
| IB/0025/G           | This was an application for a group of variations. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - product | 19/10/2016   | 23/02/2017    | SmPC               |                                   |

<div style=\"page-break-after: always\"></div>

|                     | Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer   |            | no         | SmPC and PL longer   | Refer to Scientific conclusions and grounds authorised                                         |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------|------------------------------------------------------------------------------------------------|
| PSUSA/10255 /201511 | Periodic Safety Update EU Single assessment - simeprevir                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 23/06/2016 | 18/08/2016 |                      | recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10255/201511. |
| IA/0023             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient product                                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/07/2016 | n/a        |                      |                                                                                                |
| II/0021             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 07/07/2016 | n/a        |                      |                                                                                                |
| II/0015             | Update of sections 4.2, 4.4, 4.5, 4.8 and 5.1 of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 26/05/2016 | 30/06/2016 | SmPC,                | The current product information for OLYSIO includes a                                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

|         | SmPC in order to amend the safety information regarding the use of Olysio in interferon-free regimens, based on the primary analysis (SVR12) of studies HPC3017 and HPC3018. The Package Leaflet and Labelling are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | no                    | Labelling and PL recommendation for the interferon-free simeprevir and sofosbuvir ribavirin which is based on study and real-world clinical application, data from the HPC3017/OPTIMIST-1 and are presented and the MAH 4.2, 4.4, 4.5, 4.8 and 5.1 studies. Data submitted confirms combination given 12 weeks without cirrhosis and shows to the 12 weeks regimen and maximal efficacy. In cirrhotic patients, data in cirrhotic patients when without RBV. Therefore, this recommended in cirrhotic may be considered for risk for clinical disease longer   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0020 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data product                                                                                                                                                                              | 09/06/2016 n/a        | [cirrhotic] progression subsequent retreatment options.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0017 | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                           | 28/01/2016 30/06/2016 | SmPC and Annex II                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0016 | B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold                                                                                                                                                                                                                                                        | 10/12/2015 n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                     | increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                             |            |               |                        |                                                                                                                                            |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10255 /201505 | Periodic Safety Update EU Single assessment - simeprevir                                                                                                                                                                                                                                                                                                                                                            | 03/12/2015 | n/a           |                        | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10255 /201411 | Periodic Safety Update EU Single assessment - simeprevir                                                                                                                                                                                                                                                                                                                                                            | 25/06/2015 | 20/08/2015    | SmPC, Labelling and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10255/201411. |
| II/0011             | Update of sections 4.5 and 5.2 of the SmPC in order to add new preclinical data on the in vitro inhibitory potential of simeprevir on human OCT2, BCRP and OATP1B3. In addition, a minor change was introduced in section 5.1 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                        | 23/07/2015 | 30/06/2016 no | SmPC longer            |                                                                                                                                            |
| II/0008             | Update of sections 4.2, 4.8 and 5.2 of the SmPC in order to add information on the use of the product in East Asian patients based on the results of the HPC3005 study. Minor editorial amendments are introduced in section 5.1 of the SmPC. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product | 23/07/2015 | 30/06/2016    | SmPC and PL            |                                                                                                                                            |
| II/0004/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                  | 23/07/2015 | n/a           |                        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                | longer authorised                 |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------|
| II/0012   | Update of sections 4.2 and 4.4 of the SmPC in order to remove information limiting the use of IFN-free therapy with Olysio to patients who are intolerant to, or ineligible for, IFN therapy and are in urgent need of treatment. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                     | 25/06/2015 20/08/2015 SmPC no     |
| II/0007/G | This was an application for a group of variations. Update of section 4.5 of the SmPC in order to inform prescribers that co administration of simeprevir with ledipasvir is not recommended while no dose adjustment is needed when simeprevir is given concomitantly with dolutegravir. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to product | 25/06/2015 20/08/2015 SmPC and PL |

<div style=\"page-break-after: always\"></div>

|           | new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                               |            |               |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0010/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.d.2.b - Change in test procedure for the finished product - Deletion of a test procedure if an alternative method is already authorised | 07/05/2015 | n/a           | longer      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IG/0531   | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                         | 05/03/2015 | n/a           |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0003   | Update of section 4.2 of the SmPC in order to adjust to≥25 IU/ml the HCV RNA threshold for the treatment stopping rule at week 12 and week 24. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product                                   | 26/02/2015 | 20/08/2015 no | SmPC        | Treatment stopping rules in patients receiving OLYSIO in combination with peginterferon alfa and ribavirin with inadequate on-treatment virologic response have been updated after analyses of data obtained using samples from the clinical studies which have indicated same HCV RNA threshold for all the time points of treatment. As a consequence, treatment with peginterferon alfa and ribavirin should be discontinued at treatment week 12 or 24 when the HCV RNA load is ≥ 25 IU/ml. |
| IA/0006   | B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                                                                          | 10/02/2015 | n/a           |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| II/0002   | Update of sections 4.2, 4.4, 4.8,5.1 and 5.2 of the SmPC in order reflect the final result of studies C212 (co-infected), HPC3011 (Genotype 4), HP2002 (Cosmos study). In addition, some editorial changes                                                                                                 | 22/01/2015 | 20/08/2015    | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

|         | are included. Package leaflet and labelling are updated in accordance. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0001 | Update of sections 4.4 and 4.5 of the SmPC in order reflect a recommendation not to combine simeprevir and ciclosporin in organ transplant patients and information on interactions and dose recommendation when simeprevir is co-administered with other immunosuppressants. In addition, minor editorial changes have been introduced throughout the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data 18/12/2014 20/08/2015 product no | SmPC The current update of the Product Information reflects the interim analysis of the preliminary PK data from the Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Patients with Recurrent Chronic Hepatitis C Genotype 1b Infection after Orthotopic Liver transplantation (preliminary pharmacokinetic analysis of simeprevir and daclatasavir plasma concentrations of Part 1). The planned analysis showed on average 5-times higher simeprevir plasma exposures in subjects with fibrosis receiving cyclosporin (CsA). Therefore the MAH proposed an update of sections 4.4 and 4.5 of the SmPC in order reflect a recommendation not to combine simeprevir and ciclosporin in organ transplant patients and information on interactions and dose recommendation when simeprevir is co-administered with other immunosuppressants. longer |

are included. Package leaflet and labelling are updated in accordance. Update of sections 4.4 and 4.5 of the SmPC in order reflect a recommendation not to combine simeprevir and ciclosporin in organ transplant patients and information on interactions and dose recommendation when simeprevir is co-administered with other immunosuppressants. In addition, minor editorial changes have been introduced throughout the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data 18/12/2014 20/08/2015 SmPC Medicinal product no longer authorised